Kristian Reich
#127,321
Most Influential Person Now
Researcher
Kristian Reich's AcademicInfluence.com Rankings
Kristian Reichcomputer-science Degrees
Computer Science
#5408
World Rank
#5716
Historical Rank
Computational Linguistics
#744
World Rank
#757
Historical Rank
Machine Learning
#1428
World Rank
#1450
Historical Rank
Artificial Intelligence
#1659
World Rank
#1691
Historical Rank
Download Badge
Computer Science
Kristian Reich's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Kristian Reich Influential?
(Suggest an Edit or Addition)Kristian Reich's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Secukinumab in plaque psoriasis--results of two phase 3 trials. (2014) (1575)
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008) (1056)
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial (2005) (1002)
- Definition of treatment goals for moderate to severe psoriasis: a European consensus (2010) (729)
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015) (706)
- European S3‐Guidelines on the systemic treatment of psoriasis vulgaris (2009) (668)
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (2015) (474)
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. (2015) (474)
- Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. (2014) (441)
- Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA (2017) (424)
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (2017) (386)
- European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC (2015) (381)
- A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis (2016) (363)
- Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up (2013) (363)
- Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis (2009) (352)
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (2016) (346)
- Epidemiology and comorbidity of psoriasis in children (2010) (338)
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) (2018) (311)
- The concept of psoriasis as a systemic inflammation: implications for disease management (2012) (304)
- Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. (2010) (300)
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. (2011) (295)
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (2015) (266)
- Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany (2008) (260)
- S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update (2012) (259)
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. (2016) (255)
- The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement (2008) (253)
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study (2017) (253)
- Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial (2015) (227)
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials (2012) (209)
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials (2020) (207)
- Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis (2014) (201)
- Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey (2009) (195)
- A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. (2011) (189)
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial (2019) (187)
- Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data (2019) (180)
- Nail psoriasis in Germany: epidemiology and burden of disease (2010) (173)
- Efficacy and safety of infliximab vs. methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1) (2011) (171)
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. (2019) (168)
- Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. (2008) (166)
- Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up (2015) (153)
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial (2019) (151)
- Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study (2017) (148)
- Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis (2015) (143)
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension (2012) (142)
- Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis – A retrospective study (FUTURE) (2009) (141)
- Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer‐blind phase III study in comparison with a registered methyl‐5‐aminolaevulinate cream and placebo (2012) (139)
- Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey (2015) (135)
- Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. (2005) (135)
- Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. (2019) (133)
- The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) (2016) (131)
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies (2011) (128)
- A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis (2014) (126)
- Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial (2006) (126)
- Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials (2019) (126)
- Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. (2001) (124)
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (2012) (122)
- European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC (2017) (120)
- Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema (2015) (119)
- Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. (2002) (119)
- Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis (2014) (119)
- Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. (2009) (118)
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest (2015) (117)
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2) (2018) (117)
- Approach to managing patients with nail psoriasis (2009) (115)
- Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. (2005) (114)
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment (2018) (111)
- Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study (2006) (110)
- Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. (2012) (109)
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) (2007) (109)
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. (2010) (109)
- TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. (2007) (108)
- Optimization of photodynamic therapy with a novel self‐adhesive 5‐aminolaevulinic acid patch: results of two randomized controlled phase III studies (2009) (107)
- A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes (2009) (107)
- Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data (2017) (105)
- Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double‐blind, placebo‐controlled phase III study (2010) (103)
- Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. (2000) (101)
- Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2) (2013) (100)
- German S3-guidelines on the treatment of psoriasis vulgaris (short version) (2012) (100)
- Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study (2007) (98)
- Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. (2003) (96)
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis (2020) (96)
- Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3) (2017) (95)
- Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris (2007) (94)
- Cytokine gene polymorphisms in allergiccontact dermatitis (2003) (91)
- S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011 (2011) (90)
- An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017) (89)
- Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. (1999) (89)
- Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. (2005) (88)
- Patient-relevant treatment goals in psoriasis (2016) (87)
- Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. (2020) (86)
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials (2017) (85)
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (85)
- Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (2019) (85)
- A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial (2009) (85)
- Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). (2007) (85)
- Clinical meaningfulness of complete skin clearance in psoriasis. (2016) (84)
- Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. (2002) (82)
- EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations (2020) (81)
- The genetic basis for most patients with pustular skin disease remains elusive (2018) (81)
- Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. (2010) (80)
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021) (79)
- German psoriasis registry PsoBest: objectives, methodology and baseline data (2014) (79)
- Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization (2000) (78)
- Bimekizumab versus Secukinumab in Plaque Psoriasis. (2021) (78)
- Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis (2013) (77)
- Genetic factors in contact allergy—review and future goals (2011) (75)
- Psoriasis--new insights into pathogenesis and treatment. (2009) (74)
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (2021) (74)
- Long‐term follow‐up of photodynamic therapy with a self‐adhesive 5‐aminolaevulinic acid patch: 12 months data (2010) (73)
- Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials (2020) (72)
- Quality of psoriasis care in Germany – results of the national study PsoHealth 2007 (2008) (72)
- Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA‐S, a phase 3 study (2019) (72)
- Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus (2018) (71)
- Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) (2018) (71)
- An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. (2012) (70)
- Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial (2014) (69)
- Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus (2011) (68)
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial† (2019) (68)
- Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial (2019) (68)
- Non‐adherence and measures to improve adherence in the topical treatment of psoriasis (2014) (68)
- In touch with psoriasis: topical treatments and current guidelines (2011) (66)
- Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database (2018) (65)
- Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis (2015) (63)
- Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes? (2006) (63)
- Engagement of the FcεRI Stimulates the Production of IL-16 in Langerhans Cell-Like Dendritic Cells1 2 (2001) (62)
- Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. (2019) (61)
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study (2016) (60)
- Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis. (2016) (60)
- Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice (2019) (59)
- Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial (2010) (59)
- Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease (2001) (58)
- Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study (2018) (58)
- N‐acetyltransferase 1 and 2 polymorphisms in para‐substituted arylamine‐induced contact allergy (2000) (58)
- Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3) (2017) (58)
- Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. (2003) (57)
- Treatment of psoriasis with interleukin-10. (1998) (57)
- Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. (2001) (56)
- Bimekizumab versus Adalimumab in Plaque Psoriasis. (2021) (56)
- Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study (2011) (55)
- Treatment goals in psoriasis (2007) (54)
- Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. (2019) (54)
- Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study (2019) (54)
- The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab (2008) (54)
- Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. (2011) (53)
- Cytokine gene polymorphisms in atopic dermatitis (2003) (52)
- Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis (2009) (52)
- Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study (2013) (51)
- Prospective validation of ‘Allergy‐Control‐SCORETM’: a novel symptom–medication score for clinical trials (2011) (51)
- Tumor necrosis factor antagonists in the therapy of psoriasis. (2008) (51)
- Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes (2014) (50)
- Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE (2011) (49)
- Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate‐to‐severe plaque psoriasis (2017) (49)
- The German National Program on Psoriasis Health Care 2005–2015: results and experiences (2016) (48)
- Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies (2019) (48)
- Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis (2007) (48)
- Nail psoriasis as a severity indicator: results from the PsoReal study (2010) (48)
- Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials (2018) (47)
- Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus (2012) (47)
- Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials (2018) (47)
- Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. (2002) (47)
- Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. (2009) (46)
- Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis (2009) (46)
- The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. (2020) (46)
- Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma (2006) (45)
- Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial (2017) (45)
- Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis , psoriatic arthritis , and ankylosing spondylitis : integrated pooled clinical trial and postmarketing surveillance data (2019) (45)
- Genotype and phenotype of N‐acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy (1998) (44)
- Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study (2017) (44)
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations (2018) (43)
- Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2 (2011) (43)
- Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) (2017) (43)
- Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting (2011) (42)
- Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study (2020) (42)
- EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations (2021) (42)
- No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma (2005) (42)
- Topical long‐term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice (2014) (41)
- IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study (2021) (40)
- Efficacy and safety of methantheline bromide (Vagantin®) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo‐controlled trial (2012) (40)
- Digestive system in psoriasis: an update (2017) (40)
- Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus (2008) (39)
- Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1 (2009) (38)
- Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients (2005) (38)
- Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure (2019) (38)
- The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis (2011) (37)
- Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. (1999) (37)
- A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64‐week multinational randomized phase IV study in 1790 patients (PSO‐TOP) (2017) (36)
- Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3” (2016) (36)
- Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients (2019) (36)
- Systemic treatment with corticosteroids in psoriasis–health care provision far beyond the S3‐guidelines (2011) (35)
- Use of fumaric acid esters in psoriasis. (2007) (35)
- Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials (2020) (35)
- Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases (2008) (35)
- Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ) (2014) (35)
- Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. (2010) (34)
- Treatment of severe psoriasis and psoriatic arthritis with leflunomide (2002) (34)
- One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis (2014) (34)
- Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) * (2021) (33)
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) (2018) (33)
- Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials (2007) (33)
- Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3 (2017) (32)
- [S3-Guidelines for the therapy of psoriasis vulgaris]. (2006) (32)
- An open‐label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids (2011) (32)
- Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study (2011) (32)
- Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study (2021) (32)
- Cyclosporine therapy in dermatology (2009) (31)
- Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results. (2021) (31)
- Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. (1999) (31)
- Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials (2018) (31)
- Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. (2007) (31)
- Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials (2019) (30)
- CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin‐10‐induced regression to macrophage‐like monocytes (2008) (30)
- What is new in topical therapy for psoriasis? (2011) (30)
- Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. (2021) (29)
- Association analysis of IL20RA and IL20RB genes in psoriasis (2008) (29)
- Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS) (2013) (29)
- Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis (2008) (29)
- Differential Changes in Inflammatory Mononuclear Phagocyte and T Cell Profiles within Psoriatic Skin during Treatment with Guselkumab versus Secukinumab. (2021) (28)
- Australasian College of Dermatologists Abstracts Presented at the 52nd Annual Scientific Meeting 18–21 May 2019 Melbourne Convention and Exhibition Centre Melbourne, Victoria (2019) (28)
- Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study (2016) (28)
- ["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]. (2009) (27)
- Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. (2018) (27)
- No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study (2012) (27)
- [15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. (2009) (27)
- COVID‐19 and implications for dermatological and allergological diseases (2020) (27)
- A new instrument for the assessment of patient‐defined benefit in the treatment of allergic rhinitis (2011) (27)
- Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study (2020) (27)
- Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL) (1997) (27)
- Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. (2011) (26)
- The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis (2017) (26)
- Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies (2015) (26)
- Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease (2019) (26)
- Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. (2009) (25)
- Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study * (2020) (25)
- Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies (2018) (25)
- Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. (2001) (25)
- Treatment goals in psoriasis routine care (2015) (25)
- Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. (2016) (25)
- Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. (2008) (25)
- Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis (2014) (24)
- Cost‐of‐illness of psoriasis – results of a German cross‐sectional study (2018) (24)
- A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment (2019) (23)
- Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis (2017) (23)
- Transition to ustekinumab in patients with moderate‐to‐severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) (2014) (22)
- Psoriasis and metabolic syndrome in children: current data (2017) (22)
- Allergic Contact Dermatitis and Atopic Eczema (2006) (22)
- Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study (2009) (21)
- Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long‐term psoriasis management (2018) (21)
- Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study (2015) (21)
- Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study) (2016) (20)
- Granulocyte colony‐stimulating‐factor‐induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation (2004) (20)
- Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab† (2019) (20)
- Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28 (2019) (20)
- Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study (2020) (20)
- Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial (2022) (20)
- Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (2017) (19)
- Rational for statin use in psoriatic patients (2013) (19)
- Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials (2020) (18)
- Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab (2013) (18)
- Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician–patient interaction and communication (2017) (18)
- Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials (2015) (18)
- Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies† (2019) (18)
- Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study (2017) (18)
- An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals (2013) (18)
- Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate‐to‐severe plaque psoriasis (FAST) (2017) (18)
- Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. (2018) (17)
- Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years (2019) (17)
- Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. (2008) (17)
- How do regional factors influence psoriasis patient care in Germany? (2010) (17)
- German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations (2021) (17)
- Drug supply for children with psoriasis in Germany (2013) (17)
- Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP) (2014) (17)
- Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. (2017) (16)
- Health Services Research in Psoriasis – The German Approach (2009) (16)
- The interpretation of long‐term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials (2013) (16)
- Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2 * (2021) (16)
- Variations in the genes encoding the peroxisome proliferator-activated receptors α and γ in psoriasis (2004) (15)
- Glyceryl (mono)caprylate – a new contact allergen (2013) (15)
- A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL) (2020) (15)
- Mouse models of atopic dermatitis: a critical reappraisal (2020) (15)
- Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations (2017) (14)
- Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab” (2010) (14)
- Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. (2019) (14)
- Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data (2022) (14)
- IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE) (2021) (14)
- Influence of psoriasis on circulatory system function assessed in echocardiography (2015) (13)
- Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials (2020) (13)
- Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis. (2010) (13)
- Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial (2020) (13)
- Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials (2017) (13)
- Patient-relevant needs and treatment goals in nail psoriasis (2016) (13)
- Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. (2007) (13)
- Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris (2008) (12)
- Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study * (2020) (12)
- 388 Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis (2016) (12)
- Neutrophilic urticarial dermatosis (NUD) indicating Cryopyrin‐associated periodic syndrome associated with a novel mutation of the NLRP3 gene (2016) (12)
- Variations in the peroxisome proliferator-activated receptor-γ gene and melanoma risk (2007) (12)
- Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2) (2020) (11)
- [New information about fumaric acid esters (Fumaderm): results of a workshop of experts]. (2011) (11)
- Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care (2020) (11)
- German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations (2021) (11)
- Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial * (2022) (11)
- Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method (2021) (11)
- A close look at autoimmune muscle disorders: association of Lambert–Eaton myasthenic syndrome with dermatomyositis (2004) (11)
- Case reports of PML in patients treated for psoriasis. (2013) (11)
- Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: Results of a randomized, open‐label trial (2008) (10)
- Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies (2020) (10)
- Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis (2017) (10)
- Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, doubleblind, placebo-controlled study (2009) (10)
- A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patients (2016) (10)
- [Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy]. (2012) (10)
- Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study (2016) (10)
- Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis (2021) (10)
- Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. (2004) (10)
- A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain (2017) (9)
- First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis (2017) (9)
- Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3 (2020) (9)
- SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs (2013) (9)
- Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017 (2021) (9)
- Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach (2020) (9)
- FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study (2016) (9)
- Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study (2021) (8)
- Exposure‐Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis (2018) (8)
- Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) (2021) (8)
- [Psoriasis arthritis. An interdisciplinary challenge]. (2011) (8)
- Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab (2020) (8)
- What is psoriasis? – Perception and assessment of psoriasis among the German population (2018) (8)
- Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study * (2021) (8)
- Treatment adherence: a hurdle for real‐life effectiveness in psoriasis? (2014) (8)
- A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS) (2021) (8)
- Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study. (2019) (8)
- The maturation‐dependent production of interleukin‐16 is impaired in monocyte‐derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF‐α and IL‐1β (2004) (8)
- Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial. (2022) (8)
- Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study (2021) (8)
- Prospective validation of the “rhino conjunctivitis allergy-control-SCORE©” (RC-ACS©) (2012) (8)
- [Cutaneous granulomatous reactions at botulinum neurotoxin A injection sites: First manifestation of systemic sarcoidosis]. (2015) (7)
- Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4) * (2022) (7)
- Methotrexate therapy in dermatology (2012) (7)
- Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis (2021) (7)
- [Paradoxical skin reactions under therapy with TNF-alpha antagonists]. (2013) (7)
- More on PML in Patients Treated with Dimethyl Fumarate. (2016) (7)
- Immunoglobulin E-Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis. (2019) (7)
- National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines (2013) (7)
- Continued treatment with secukinumab is associated with high retention or regain of response (2019) (7)
- Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany (2021) (7)
- A phase 4, randomized, head‐to‐head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate‐to‐severe plaque psoriasis (CHANGE) (2020) (7)
- Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease (2014) (6)
- Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (2021) (6)
- Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis (2021) (6)
- Outcome assessment and treatment goals (2008) (6)
- The value of subcutaneous vs. oral methotrexate: real‐world data from the German psoriasis registry PsoBest (2020) (6)
- Treatment of pyoderma gangrenosum with topical tacrolimus (1998) (6)
- Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0: A Validation Study. (2019) (6)
- ixekizumab, a novel anti–il-17a antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis : 3232 (2016) (6)
- International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. (2022) (6)
- Physician- and patient-reported outcomes with apremilast for patients with plaque psoriasis during routine dermatology care in Germany: A second interim analysis (2018) (6)
- Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways (2019) (6)
- Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL) (2020) (6)
- FRI0445 Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis (2016) (6)
- Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care (2020) (6)
- 058 Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3 (2016) (6)
- Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis (2021) (6)
- Scalp psoriasis (2011) (6)
- Histology and Serum Cytokine Responses in an Imported Rickettsia slovaca Infection, Germany. (2018) (6)
- Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis (2019) (6)
- FRI0511 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses (2017) (5)
- Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". (2010) (5)
- The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis (2022) (5)
- Extensive hyperpigmentation of the face in a Filipina (2017) (5)
- From relative to absolute treatment outcomes—Correlation of PASI 90 and PASI ≤2 in three clinical trials with secukinumab (2018) (5)
- Infliximab in the treatment of psoriasis (2006) (5)
- Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2 (2019) (5)
- Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) (2018) (5)
- Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3 (2022) (5)
- Psoriasis inversa (2015) (5)
- Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study (2017) (4)
- Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care (2020) (4)
- 002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis (2017) (4)
- Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials (2018) (4)
- Generalized pustular psoriasis: overview of the status quo and results of a panel discussion (2022) (4)
- Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies (2018) (4)
- Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis (2021) (4)
- 398 Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3) (2017) (4)
- 477 Consistency of response across subgroups of patients with moderate-to-severe plaque psoriasis following 52 weeks of treatment with ixekizumab compared to ustekinumab (2018) (4)
- 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses (2017) (4)
- Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials (2022) (4)
- [New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. (2012) (4)
- Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO (2021) (4)
- Which PASI Outcome Is Most Relevant to the Patients in Real-World Care? (2021) (4)
- Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays (2016) (4)
- Tumor necrosis factor polymorphisms in psoriatic arthritis: association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele (2007) (3)
- 056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2 (2016) (3)
- Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis (2018) (3)
- [The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung]. (2003) (3)
- Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal (2020) (3)
- Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3 (2021) (3)
- Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials (2019) (3)
- LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2 (2018) (3)
- 053 Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER Trials): Adjudicated data from the induction period (2016) (3)
- Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (2017) (3)
- 15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2) (2020) (3)
- Effect of tildrakizumab on personal relationships in patients with moderate-to-severe chronic plaque psoriasis (2018) (3)
- Ten years of infliximab: its role in dermatology. (2009) (3)
- Regulatory functions of IL-10 in the cutaneous immune system: a lesson to learn from experimental IL-10 therapy of inflammatory skin disease (2001) (3)
- Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy. (2005) (3)
- Double-blind hydrocortison-controlled tacrolimus ointment for atopic dermatitis (1998) (3)
- 28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment (2021) (3)
- Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis (2019) (3)
- [Evidence-based therapy of Raynaud's syndrome]. (2006) (3)
- Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial (2022) (3)
- SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis (2013) (3)
- AB0771 Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the liberate study (2017) (3)
- Dear‐Doctor‐Letter Fumaderm® – What are the facts? (2013) (3)
- THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses (2018) (3)
- 15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials (2020) (3)
- PSY5 IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS (2009) (3)
- Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study. (2022) (2)
- [Psoriasis--clinical picture and current therapy]. (2009) (2)
- Network meta‐analyses in psoriasis: overview and critical discussion (2021) (2)
- 15-Deoxy-delta 12 , 14-prostaglandin J 2 inhibits glucocorticoid binding and signalling in macrophages through a peroxisome proliferator-activated receptor gamma-independent process (2)
- Giant Primary Melanoma With No Apparent Metastases: A Report of 2 Cases (2017) (2)
- Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials (2022) (2)
- Contact sensitization to essential oils: IVDK data of the years 2010–2019 (2022) (2)
- 33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study (2022) (2)
- Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) (2017) (2)
- Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis (2019) (2)
- ixekizumab shows no association with major adverse cardiac events (mace) in patients with moderate-to-severe psoriasis: An integrated safety analysis of clinical trials : 3413 (2016) (2)
- 16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis (2020) (2)
- PSS44 USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (2)
- Evidence for a role of langerhans cell-derived interleukin-16 in atopic dermatitis (2002) (2)
- 041 Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis (2021) (2)
- Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. (2012) (2)
- Severe ulcerative penile leishmaniasis--Importance of PCR-based diagnostics. (2015) (2)
- Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". (2017) (2)
- Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) (2019) (2)
- In touch with psoriasis: a patient‐centred approach to therapy (2011) (2)
- Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2019) (2)
- Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis (2018) (2)
- Efficacy and safety comparison of photodynamic therapy with BF-200 ALA versus Metvix (R) for the treatment of actinic keratosis: A prospective, randomized, lacebo-controlled multinational, phase III study (2011) (2)
- An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study (2022) (2)
- Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab. (2022) (2)
- THU0413 Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis (Esteem 1 and 2) (2015) (2)
- Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials (2021) (2)
- Immunogenicity with tildrakizumab, an anti–IL-23p19 monoclonal antibody, in a pooled analysis of three randomized controlled trials in patients with chronic plaque psoriasis (2018) (2)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up) (2021) (2)
- FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis (2016) (2)
- Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: A pooled subanalysis of ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT) (2018) (2)
- Genetic diagnostics in inflammatory dermatoses – from insights into pathophysiology to individualized patient management (2013) (2)
- Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2019) (2)
- Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment (2020) (2)
- Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) (2017) (2)
- Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance (2022) (2)
- 15328 Efficacy and safety of mirikizumab in patients with moderate to severe plaque psoriasis: 104-week results from a randomized phase 2 study (2020) (2)
- The hair follicle‐psoriasis axis: Shared regulatory mechanisms and therapeutic targets (2021) (2)
- Letter to the Editor in Response to recently published article, ‘Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis’ (2017) (2)
- Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study (2018) (2)
- Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis (2021) (1)
- Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study (2018) (1)
- PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (1)
- 13677 Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial (2020) (1)
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies (2020) (1)
- Evidence against a TH2 cytokine profile in early stage cutaneous T-cell-lymphoma (1998) (1)
- Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial (2021) (1)
- 13771 Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate to severe psoriasis: 24-week results from a multicenter, randomized, open-label, rater-blinded study (SPIRIT-H2H) (2020) (1)
- Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies (2019) (1)
- 26589 Spesolimab, an IL-36R inhibitor, may reduce symptoms of pain in patients with palmoplantar pustulosis – Results from a small pilot study (2021) (1)
- Correction to: Digestive system in psoriasis: an update (2017) (1)
- 076. CONSISTENT SAFETY AND TOLERABILITY OF SECUKINUMAB OVER LONG-TERM EXPOSURE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND MODERATE TO SEVERE PLAQUE PSORIASIS: UPDATED POOLED SAFETY ANALYSES (2017) (1)
- 060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials (2016) (1)
- Safety and tolerability of tildrakizumab, an anti–interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: Results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2) (2018) (1)
- Skin Manifestations of Neonatal Lupus Erythematosus (2014) (1)
- A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis (2020) (1)
- FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA (2020) (1)
- Ustekinumab for the treatment of plaque psoriasis (2009) (1)
- [Psoriasis-associated keratitis: case report]. (2014) (1)
- Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review (2022) (1)
- Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. (2022) (1)
- Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. (2022) (1)
- [Therapy of psoriasis vulgaris with efalizumab]. (2006) (1)
- 25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial (2021) (1)
- OP0114 MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM (2019) (1)
- AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis (2018) (1)
- Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. (2022) (1)
- THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study (2016) (1)
- 257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses (2019) (1)
- Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study (2020) (1)
- Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study. (2020) (1)
- 009 PASI ≤ 2 corresponds to PASI 90, irrespective of baseline severity: A post-hoc analysis of the PRIME-study (2017) (1)
- Health Related Quality of Life-Outcome in National Care - Real World Data from the German Psoriasis-Registry “Psobest” (2013) (1)
- Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest (2022) (1)
- 27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial (2021) (1)
- Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris. (2021) (1)
- Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program (2019) (1)
- Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment (2018) (1)
- How many people develop anti‐drug antibodies to the biologic drug tildrakizumab, and what impact does this have on the effectiveness of their treatment (2020) (1)
- Expression of the CD4+ cell-specific chemoattractant IL-16 in cutaneous T cell lymphoma (1998) (1)
- Treatment of Psoriasis: Focus on Clinic-Based Management with Infliximab (2014) (1)
- 16317 Characterization of patient clusters based on response to treatment with secukinumab: A “pattern recognition” analysis of pooled phase 3 data (2020) (1)
- Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. (2015) (1)
- T-cell-clones from lesional skin of cutaneous T-cell-lymphoma express functional CD95 (1998) (1)
- FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES (2020) (1)
- Hemin-induced Hmox-1 Associated With Downregulation Of Atrogin-1 And Murf-1 In C2c12 Myotubes: 635 (2009) (0)
- Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway (2020) (0)
- AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2 (2020) (0)
- Chronic mucocutaneous Candidiasis with proof of STAT1 Mutation in Childhood (2013) (0)
- Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (2018) (0)
- IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance (2019) (0)
- 14998 Reductions in absolute PASI over 144 weeks of treatment with certolizumab pegol in patients with plaque psoriasis: Pooled analysis from two phase 3 trials (CIMPASI-1 and CIMPASI-2) (2020) (0)
- 054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial (2016) (0)
- Safety in National Care - Real World Data from the German Psoriasis-Registry “Psobest” (2013) (0)
- 27900 Maintaining long-term improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe plaque psoriasis treated with guselkumab: VOYAGE 2, 5-year data (2021) (0)
- 13843 Baseline burden of disease in patients with mild to moderate versus severe psoriasis: Insights from LAPIS-PSO reflecting routine dermatology care in germany (2020) (0)
- 25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial (2021) (0)
- Newsletter No. 6/2009 (2009) (0)
- A study of the drug tildrakizumab in psoriasis patients (2020) (0)
- 27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) (2021) (0)
- 26248 Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study (2021) (0)
- 27629 Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population (2021) (0)
- Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2 (2021) (0)
- Current and future oral small molecules (2017) (0)
- ESDR041 - Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis (2021) (0)
- Development and Validation of a Melanoma Risk Score Based on PooledData from 16 Case – Control Studies (2015) (0)
- Association of rapid acetylator phenotype with juvenile onset psoriasis (1998) (0)
- Higher Levels of Response on Clinical Atopic Dermatitis Severity Measures Are Associated with Meaningful Improvements in Patient-Reported Symptom and Quality of Life Measures: Integrated Analysis of Three Upadacitinib Phase 3 Trials. (2023) (0)
- P82: Long‐term efficacy of abrocitinib after initial successful treatment in patients with atopic dermatitis (2022) (0)
- The efficacy of secukinumab with continued use in the treatment of psoriasis (2020) (0)
- 15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years (2020) (0)
- 25385 Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analyses from phase III studies in psoriasis and psoriatic arthritis (PsA) (2021) (0)
- 15431 Indirect comparisons in psoriasis: Implications for clinical practice (2020) (0)
- Safety of guselkumab in patients with psoriasis treated through 100 weeks (2019) (0)
- Abstract 868: Prevalence, Underdiagnosis, and Undertreatment of Cardiovascular Risk Factors in Patients With Moderate-to-Severe Psoriasis (2009) (0)
- Controversies in Experimental Dermatology (2006) (0)
- PBI3 Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis (2021) (0)
- Contents Vol. 218, 2009 (2008) (0)
- Secukinumab’s pooled and long-term safety remains favorable up to five years of treatment in 19 psoriasis clinical trials (2018) (0)
- Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials (2020) (0)
- Reviewers' list (2005) (0)
- PSK1 EFFICACY OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS: A META-ANALYSIS (2006) (0)
- Focus - Use of fumaric acid esters in psoriasis (2007) (0)
- Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment (2023) (0)
- Apremilast Was Associated with an Acceptable Safety Profile in ESTEEM Trials (2014) (0)
- 17570 Secukinumab demonstrated high efficacy in clearing nail psoriasis: Results from posthoc analyses from the phase III programs (2020) (0)
- 16238 Online case-based education improves dermatologists’ knowledge and confidence in introducing novel agents for psoriasis into clinical practice (2020) (0)
- Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT) (2020) (0)
- What is the Best Target for Psoriasis : IL-23 Versus IL-17 A ? Doctor (2018) (0)
- Infection rates in the ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up (2012) (0)
- Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. (2023) (0)
- Erratum (2011) (0)
- Definition of psoriasis severity (2018) (0)
- Measuring patient‐relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10‐item short form (2022) (0)
- 25597 Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis (2021) (0)
- Comparison of guselkumab with placebo and adalimumab on health-related quality of life in a phase 2b clinical trial X-PLORE (2016) (0)
- 26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial (2021) (0)
- Subject Index Vol. 216, 2008 (2008) (0)
- PSS28 Long-Term Improvement in Patient-Reported Outcomes After Transition From Methotrexate to Ustekinumab in Moderate to Severe Psoriasis: Transit Week 52 Results (2012) (0)
- [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. (2009) (0)
- Use of fumaric acid esters in psoriasis Use of fumaric acid esters in psoriasis (2007) (0)
- The Impact of introducing DRG on Functional Abilities and Comorbidity of Patients in a Rehabilitation Centre (0)
- Interleukin-23 in Psoriasis: Integrating New Therapies in the Current Treatment Landscape (2018) (0)
- [Inverse psoriasis]. (2015) (0)
- A new treatment option for paediatric psoriasis (2020) (0)
- New Treatments Significantly Improve Responses in Patients With Plaque Psoriasis (2015) (0)
- Author index (2005) (0)
- A trial to compare the biologic drug ixekizumab with two other treatments for psoraisis, fumaric acid esters and methotrexate (2020) (0)
- [Skin as manifestation organ for inflammatory rheumatic diseases]. (2013) (0)
- 15188 Clinical responses by self-reported PsA status at baseline among patients with moderate to severe psoriasis treated with guselkumab versus secukinumab: Week 48 results from the ECLIPSE study (2020) (0)
- Latest Highlights from Guselkumab in Psoriasis (2019) (0)
- Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis (2010) (0)
- 13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis (2020) (0)
- PSS26 Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): An Integrated Approach of Outcomes Measurement in Nail Psoriasis (2012) (0)
- A plaidoyer for the use of human skin xenotransplant mouse models in preclinical psoriasis research (2022) (0)
- Comparative functional analysis of skin infiltrating T-cells in early stage mycosis fungoides and benign eczema (1998) (0)
- 534 Effects on CD3, Treg and TH17 cell numbers in skin biopsies after 16-week mirikizumab treatment, evaluated by an epigenetic assay (2019) (0)
- Subject Index Vol. 218, 2009 (2008) (0)
- Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (2022) (0)
- Psoriasis: Looking Deeper into Skin and Nail Disease (2010) (0)
- [Infliximab. Role in the treatment of psoriasis]. (2005) (0)
- 059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials (2016) (0)
- Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials (2021) (0)
- [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]. (2006) (0)
- SARS-CoV-2 vaccination status and adverse events among patients with psoriasis - data from the German Registries PsoBest and CoronaBest. (2023) (0)
- 13838 Benefits of apremilast treatment in patients with plaque psoriasis, including scalp and nail manifestations, in patients who failed to achieve adequate response or were intolerant to methotrexate treatment (2020) (0)
- 048 Effects on CD3, Treg and TH17 cell numbers in skin biopsies after 16-week mirikizumab treatment, evaluated by an epigenetic assay (2019) (0)
- Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2020) (0)
- Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2019) (0)
- PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version (1970) (0)
- Gene expression based molecular test as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded tissue, microbiopsies and tape strips. (2023) (0)
- 27078 Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2 (2021) (0)
- Contents Vol. 216, 2008 (2008) (0)
- Long-term safety and tolerability of Apremilast in patients with psoriasis: pooled safety analysis of the ESTEEM 1 and 2 trials (2015) (0)
- 15001 Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT) (2020) (0)
- IXORA-S 1 Ixekizumab provides superior efficacy compared to u stekinumab over 52-weeks of 1 treatment : results from IXORA-S , a phase 3 study 2 (2018) (0)
- 27468 Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials (2021) (0)
- Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies (2018) (0)
- Psoriasis inversa (2015) (0)
- 25529 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses (2021) (0)
- Title : Cost-of-illness of psoriasis-results of a German cross-sectional study Running head : Cost-of-illness of psoriasis in Germany (2017) (0)
- Lichen ruber erosivus - topical treatment with tacrolimus (1998) (0)
- Secukinumab Provides Greater 52-Week Sustained Relief in Dermatology-Specific Quality-of-Life Impact Than Ustekinumab (2017) (0)
- POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR (2021) (0)
- 323 A Novel, Stress-Responsive and Clinically Predictive Humanized Mouse Model of Atopic Dermatitis: Autologous Th2-Polarized Lymphocytes Suffice to Induce Characteristic Lesions in Healthy Non-Atopic Human Skin Xenotransplants In Vivo (2022) (0)
- 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis (2022) (0)
- 15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials (2020) (0)
- 14410 Impact of mirikizumab maintenance dosing at week 104 on health-related quality of life in patients who had less than PASI 90 response at week 16: A phase 2 study analysis (2020) (0)
- Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2020) (0)
- Newsletter No. 8/2009 (2009) (0)
- 500 Ixekizumab achieves more rapid reduction of circulating interleukin-19 compared to guselkumab in a psoriasis head-to-head study (2020) (0)
- Keynote lecture: psoriasis update (2008) (0)
- 15350 Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis (2020) (0)
- 33298 Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND (2022) (0)
- Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2. (2021) (0)
- 15300 Maintenance of response through up to 4-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial (2020) (0)
- A study of the drug tildrakizumab for plaque psoriasis (2020) (0)
- A matter of perspective: Imputation methods and their effects illustrated with the use of data from the PRIME study (2018) (0)
- Is Complete Skin Clearance in Psoriasis the Answer ? (2018) (0)
- 25748 Ixekizumab sustained complete clearance, itch resolution, and improved quality of life for moderate-to-severe psoriasis patients who achieved rapid, high skin clearance (2021) (0)
- Complete Skin Clearance Is Not Attained By Most Patients Receiving Biologics For Moderate To Severe Plaque Psoriasis: Interim Results of An International, Prospective, Observational Study (2016) (0)
- PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS: RESULTS FROM A PHASE III STUDY (2008) (0)
- Latest Highlights from Guselkumab in Psoriasis from EADV 2019 (2019) (0)
- Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis (2022) (0)
- Zeitmanagement und Lebensqualität nach Umstellung einer topischen und/oder Fototherapie auf Fumar-säureester bei Patienten mit Psoriasis Time Management and Quality of Life After Change of Therapy from Topical Treatment and/or Phototherapy to Fumaderm ® in Patients with Psoriasis (2011) (0)
- PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial (2019) (0)
- Effects of biologic therapies on the severity of skin symptoms and quality of life in patients with plaque-type psoriasis: a meta-analysis. (2007) (0)
- ILDS Newsletter No. 34 (2015) (0)
- 27376 Speed of clinical response and improvement in psoriasis with bimekizumab: Pooled results from the multicenter, randomized, double-blinded phase 3 BE VIVID, BE READY and BE SURE trials (2021) (0)
- Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE (2021) (0)
- Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest (2022) (0)
- Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies (2022) (0)
- 25977 Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib (2021) (0)
- 28096 Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2 (2021) (0)
- Abstracts from a congress organized by the Groupe de Recherche et d'Etude des Médiateurs de I'Inflammation. March 26, 2004. Paris, France. (2004) (0)
- 26592 Characterization of response clusters identified by unsupervised machine learning: A post hoc analysis of the head-to-head ECLIPSE trial of guselkumab and secukinumab in patients with moderate-to-severe psoriasis (2021) (0)
- Newsletter ILDS No. 14 (2010) (0)
- Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT) (2020) (0)
- 128 Transcriptional profiling of Blaschko-linear psoriasis skin highlights mostly shared but occasionally divergent features with psoriasis vulgaris (2021) (0)
- AB0952 Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: an analysis of two disease registries (2022) (0)
- Maintenance of response in moderate‐to‐severe psoriasis after withdrawal of the interleukin (IL)‐17A and IL‐17F nanobody sonelokimab: is there a role for IL‐17F in disease reoccurrence? (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kristian Reich?
Kristian Reich is affiliated with the following schools:
